Psilocybin mushrooms: Difference between revisions

Line 66:

====Neurogenesis====

A low dose (0.1 mg/kg) of psilocybin produced a trend toward increased neurogenesis in the mouse hippocampus 2 weeks after its administration, while a high dose (1 mg/kg) significantly decreased neurogenesis. These results suggest that the effects of psilocybin on neurogenesis are dose- and time-related.<ref name="pmid=27354908">{{cite journal |last1=Dos Santos |first1=RG |last2=Osório |first2=FL |last3=Crippa |first3=JA |last4=Riba |first4=J |last5=Zuardi |first5=AW |last6=Hallak |first6=JE |title=Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. |journal=Therapeutic advances in psychopharmacology |date=June 2016 |volume=6 |issue=3 |pages=193-213 |doi=10.1177/2045125316638008 |pmid=27354908 |pmc=~~PMC4910400~~}}</ref>

A low dose (0.1 mg/kg) of psilocybin produced a trend toward increased neurogenesis in the mouse hippocampus 2 weeks after its administration, while a high dose (1 mg/kg) significantly decreased neurogenesis. These results suggest that the effects of psilocybin on neurogenesis are dose- and time-related.<ref name="pmid=27354908">{{cite journal |last1=Dos Santos |first1=RG |last2=Osório |first2=FL |last3=Crippa |first3=JA |last4=Riba |first4=J |last5=Zuardi |first5=AW |last6=Hallak |first6=JE |title=Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. |journal=Therapeutic advances in psychopharmacology |date=June 2016 |volume=6 |issue=3 |pages=193-213 |doi=10.1177/2045125316638008 |pmid=27354908 |pmc=4910400}}</ref>

====Psychoplastogen====

@@ Line 66: / Line 66: @@
 ====Neurogenesis====
-A low dose (0.1 mg/kg) of psilocybin produced a trend toward increased neurogenesis in the mouse hippocampus 2 weeks after its administration, while a high dose (1 mg/kg) significantly decreased neurogenesis. These results suggest that the effects of psilocybin on neurogenesis are dose- and time-related.<ref name="pmid=27354908">{{cite journal |last1=Dos Santos |first1=RG |last2=Osório |first2=FL |last3=Crippa |first3=JA |last4=Riba |first4=J |last5=Zuardi |first5=AW |last6=Hallak |first6=JE |title=Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. |journal=Therapeutic advances in psychopharmacology |date=June 2016 |volume=6 |issue=3 |pages=193-213 |doi=10.1177/2045125316638008 |pmid=27354908 |pmc=PMC4910400}}</ref>
+A low dose (0.1 mg/kg) of psilocybin produced a trend toward increased neurogenesis in the mouse hippocampus 2 weeks after its administration, while a high dose (1 mg/kg) significantly decreased neurogenesis. These results suggest that the effects of psilocybin on neurogenesis are dose- and time-related.<ref name="pmid=27354908">{{cite journal |last1=Dos Santos |first1=RG |last2=Osório |first2=FL |last3=Crippa |first3=JA |last4=Riba |first4=J |last5=Zuardi |first5=AW |last6=Hallak |first6=JE |title=Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. |journal=Therapeutic advances in psychopharmacology |date=June 2016 |volume=6 |issue=3 |pages=193-213 |doi=10.1177/2045125316638008 |pmid=27354908 |pmc=4910400}}</ref>
 ====Psychoplastogen====